Tag: WBA

Double-Bag Options Winners

Big End to the Week: 

Options trading can become more difficult during a period exhibiting a dearth of earnings reports, as we have seen in recent weeks. However, yesterday we managed to offer up a four-pack of options ideas, and all four returned some serious intraday gain opportunities for traders.

We saw multibag gains in each and every one of the targets put forth in yesterday morning’s premarket report:

 HELE 07/17 $210-220 Calls
$210: 1.25-3.28 (+162%)
$220: .30-1.25 (+317%)
_____

WBA Weekly $42-40.50 Puts.
$42: 1.90-3.94 (+107%)
$41.50: 1.55-3.47 (+124%)
$41: .83-3.00 (+261%)
$40.50: .88-2.56 (+191%)
_____

BABA Weekly $260-270 Calls
$260: 2.37-4.91 (+107%)
$265: 1.35-2.95 (+119%)
$270: .82-1.83 (+123%)
_____

NKLA Weekly $54-57 Calls
$54: 2.18-4.42 (+103%)
$55: 1.65-3.78 (+129%)
$56: 1.35-3.19 (+136%)
$57: 1.15-2.50 (+117%)

Kronos Advanced Technology, Inc. KNOS

We also have found some sanctuary from the deleterious effects of the coronavirus through our old mainstay, OTC-traded stocks. Last month we updated readers on our April 20th call of KNOS, which had seen lows of .011 subsequent to that report.

Just under three months after our initial alert on this play, we have witnessed a high of .17, for an overall gain of 1445% Even if readers had only caught our recent June 4th update, it would have enabled the chance at some serious gains. The low following that report was .043 which, to .17, works out to an increase of 295%

Extended Watchlist:
SPAQ, OGEN, BYOC, LIACF, TPTW, CVLB

4-Pack of Options Ideas

NIO, Inc. NIO 

We tagged NIO for obserrvation to start the week on Monday, and it did end up making a notable run following that report. We saw a low of 10.70, and yesterday it hit a high of 15.28. That marks a three-session swing of 43% which we would consider decent volatility for a $10+ stock.

NIO did taper back into the close, but we will continue to monitor its activity. If it can continue to register higher lows, we won’t yet consider its run finished.

Fresh Options Ideas: 

We were in an earnings dry spell for a few weeks there, but slowly we’re beginning to see more big names coming across the calendar. This morning for earnings ideas we’ve got our sights set on a bullish and one bearish target. 

On Helen of Troy Ltd. HELE, which posted a solid beat, we’re going to focus on the HELE 07/17 $210-220 Calls.

Walgreens Boots Alliance, Inc. WBA didn’t fare as well in the last quarter as was expected of it, and we’re feeling like a short in this case might be the way to go, so we’ll tag the WBA Weekly $42-40.50 Puts.
_____

Even More New Ideas:
BABA Weekly $260-270 Calls
NKLA Weekly $54-57 Calls

Extended Watchlist:
SEGN, VAPR, VYST, DECN, PKE

Sticking with SPY Puts

Solid Hits on the SPY

We try to formulate new options ideas for a given session as often as we can without forcing the issue, and on most days we produce at least one. Yesterday, we designated our sole set of new contracts to watch as the SPY Weekly $250-248 Puts, and thanks to a painful day for the markets, we were afforded the chance to score some pretty nice intraday gains.

Two out of three of those strike points translated into instant double-bag opportunities, with the third falling just 1% short of that mark, providing the following moves on the day: 

SPY Weekly $250-248 Puts
$250: 4.39-8.73 (+99%)
$249: 4.00-8.10 (+103%)
$248: 3.65-7.50 (+105%)
______

Fresh Ideas:
SPY Weekly $244-242 Puts
WBA Weekly $44-45 Calls
KMX Weekly $50-55 Calls


CytoDyn, Inc. CYDY

We began tracking CYDY on Tuesday morning, and in addition to making a nominal move on the chart, the company has also put out some coronavirus related press in the couple days. One of the company’s investigational drugs which is about to enter Phase 2b/3 trials, has demonstrated a promising level of  efficacy among severe COVID-19 patients.

The stock itself has run from 2.65-3.09 in the past couple of sessions, which marks a move of just 17% but we’re going to be interested to continue tracking its performance in light of the company’s announcements.

VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic bio-markers.  Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio. (>>View Full PR)


Extended Watchlist:
GRYO, PNAT, ROTH, SOLI, CTYX, IPIX